CINECA IRIS Institutional Research Information System

ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases of metastatic colorectal cancer (mCRC) patients bearing rearrangements who benefited from anti-ALK, ROS, and TrkA-B-C therapies have been reported previously. Here we aimed at characterizing the clinical and molecular landscape of ALK, ROS1, and NTRK rearranged mCRC.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

Antoniotti, Carlotta;Cremolini, Chiara
Ultimo
2018-01-01

Abstract

ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases of metastatic colorectal cancer (mCRC) patients bearing rearrangements who benefited from anti-ALK, ROS, and TrkA-B-C therapies have been reported previously. Here we aimed at characterizing the clinical and molecular landscape of ALK, ROS1, and NTRK rearranged mCRC.
2018
Pietrantonio, Filippo; Di Nicolantonio, Federica; Schrock, Alexa B; Lee, Jeeyun; Tejpar, Sabine; Sartore-Bianchi, Andrea; Hechtman, Jaclyn F; Christia...espandi
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/901544
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 68
  • Scopus 197
  • ???jsp.display-item.citation.isi??? 177
social impact